STAAR Surgical (NASDAQ:STAA): Q1 Non-GAAP EPS of $0.04 beats by $0.01; GAAP EPS of $0.00 beats by $0.04.
Revenue of $35.19M (+8.0% Y/Y) beats by $0.29M.
https://seekingalpha.com/news/3570387-staar-surgical-eps-beats-0_01-beats-on-revenueWednesday, May 6, 2020
Ligand Pharmaceuticals EPS beats by $0.23, beats on revenue
Ligand Pharmaceuticals (NASDAQ:LGND): Q1 Non-GAAP EPS of $0.89 beats by $0.23; GAAP EPS of -$1.46 misses by $1.58.
Revenue of $33.16M (-23.7% Y/Y) beats by $6.46M.
https://seekingalpha.com/news/3570385-ligand-pharmaceuticals-eps-beats-0_23-beats-on-revenueVanda Pharmaceuticals EPS beats by $0.01, beats on revenue
Vanda Pharmaceuticals (NASDAQ:VNDA): Q1 GAAP EPS of $0.01 beats by $0.01.
Revenue of $58M (+21.5% Y/Y) beats by $0.58M.
Ultragenyx Pharmaceutical EPS misses by $0.37, misses on revenue
Ultragenyx Pharmaceutical (NASDAQ:RARE): Q1 GAAP EPS of -$2.05 misses by $0.37.
Revenue of $36.31M (+99.8% Y/Y) misses by $0.43M.
https://seekingalpha.com/news/3570401-ultragenyx-pharmaceutical-eps-misses-0_37-misses-on-revenueSarepta Therapeutics EPS misses by $1.75, misses on revenue
Sarepta Therapeutics (NASDAQ:SRPT): Q1 Non-GAAP EPS of -$1.04 misses by $1.75; GAAP EPS of -$0.23 misses by $0.67.
Revenue of $100.4M (+15.4% Y/Y) misses by $17.78M.
https://seekingalpha.com/news/3570415-sarepta-therapeutics-eps-misses-1_75-misses-on-revenueNuVasive EPS beats by $0.08, misses on revenue
Revenue of $259.88M (-5.4% Y/Y) misses by $2.03M.
https://seekingalpha.com/news/3570425-nuvasive-eps-beats-0_08-misses-on-revenueNeurocrine Biosciences EPS beats by $0.23, beats on revenue
Neurocrine Biosciences (NASDAQ:NBIX): Q1 Non-GAAP EPS of $0.82 beats by $0.23; GAAP EPS of $0.39 misses by $0.15.
Revenue of $237.1M (+71.3% Y/Y) beats by $10.81M.
https://seekingalpha.com/news/3570427-neurocrine-biosciences-eps-beats-0_23-beats-on-revenue
Subscribe to:
Comments (Atom)